Patent: 9,572,788
✉ Email this page to a colleague
Summary for Patent: 9,572,788
| Title: | Cell permeable inhibitors of anaphase promoting complex |
| Abstract: | The disclosure provides compositions and methods for treating cell cycle disorders. Compositions of the disclosure include proTAME, a prodrug analog of TAME and apcin, the combination of which inhibits an activity or function of the anaphase promoting complex (APC) by a synergistic mechanism. |
| Inventor(s): | King; Randall (Newton, MA), Zeng; Xing (Brookline, MA), Sackton; Katharine L. (Somerville, MA) |
| Assignee: | President and Fellows of Harvard College (Cambridge, MA) |
| Application Number: | 14/276,994 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,572,788
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2039-02-26 |
| Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2039-02-26 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2039-02-26 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2039-02-26 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
